| خلاصه مقاله | Abstract
Cell therapy, particularly through the use of chimeric antigen receptor T-cell (CAR-T) therapy, has emerged as a groundbreaking approach in the treatment of pediatric leukemia, specifically acute lymphoblastic leukemia (ALL). This innovative treatment harnesses the patient's own immune cells, which are genetically engineered to target and destroy leukemia cells more effectively. Recent clinical trials have demonstrated promising outcomes, with significant rates of remission in children who have relapsed or refractory disease, even in cases where traditional therapies have failed.
The mechanism of action involves the extraction of T cells from the patient, which are then modified to express CARs that recognize specific antigens on leukemia cells. Upon reintroduction into the patient's bloodstream, these CAR-T cells proliferate and attack the malignant cells. While the results have been encouraging, challenges remain, including the risk of severe side effects such as cytokine release syndrome (CRS) and neurotoxicity.
Moreover, ongoing research is focused on optimizing the efficacy and safety of CAR-T therapies, exploring the development of next-generation cell therapies, and understanding long-term outcomes. This evolving landscape underscores the potential of cell therapy as a pivotal treatment modality, offering hope for improved survival rates in children battling leukemia. As research progresses, it is critical to balance innovation with careful monitoring of safety to enhance the overall effectiveness of this promising therapeutic strategy. |